Clinical Trial News and Research

RSS

NewYork-Presbyterian/Columbia announces recruitment for clinical trial of robotic devices for stroke survivors

As many as half of stroke survivors lose some of their ability to move their extremities. Now specialists in rehabilitation medicine at NewYork-Presbyterian Hospital/Columbia University Medical Center are pioneering the use of robotic devices to help them regain this function. Patients are currently being recruited for ongoing clinical research trials with the new devices.

19 Jun 2010

Boehringer Ingelheim disappointed with FDA Advisory Committee recommendations on flibanserin NDA for HSDD

The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA). The FDA will consider the committee's advice as part of its final assessment of the NDA.

19 Jun 2010

Artificial pancreas system reduces risk of nocturnal hypoglycemia

An article recently published in The Lancet reports that using an artificial pancreas system overnight can significantly reduce the risk of nocturnal hypoglycemia in children and adolescents with type 1 diabetes. Moreover, the first clinical trial of an artificial pancreas system delivering both insulin and glucagon has shown that this system can prevent development of hypoglycemia.

19 Jun 2010

Conscious sedation for glioma resection shortens hospital stay

The recovery time and cost of brain-tumor surgery might both be reduced if surgery is performed while patients are awake during part of the procedure, according to a new study conducted at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

19 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.

19 Jun 2010

Childrens Hospital Los Angeles awarded $2.5M NIH grant to study risk of osteoporosis in spina bifida children

Tishya Wren, PhD, of The Saban Research Institute at Childrens Hospital Los Angeles, has received a $2.5 million grant from the National Institutes of Health - National Institute of Child Health and Human Development to study bone development in children with myelomeningocele, the most severe type of spina bifida .

19 Jun 2010

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

The Cancer Prevention and Research Institute of Texas today awarded $142 million in grants to fund innovative cancer research and prevention programs across the state. Today's announcement caps the first year of the Institute's ten year mission. Together with matching funds committed by grant recipients, more than $300 million has been invested this year in Texas' extraordinary endeavor to change the face of cancer.

19 Jun 2010

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire Pharmaceuticals, Inc. announced today that data is being presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation and poster presentations at the 33rd Annual European Cystic Fibrosis Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain.

18 Jun 2010

Curis reports net income of $4.8M for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

18 Jun 2010

Adult stem cell infusion during bypass surgery improves heart function: Study

Stem cell scientists from around the world gathered at the International Society of Stem Cell Research (ISSCR) in San Francisco to exchange information about the latest treatments with stem cells. An American company, TCA Cellular Therapy, LLC announced its FDA clinical trial results using adult stem cells in patients with history of a heart attack during open heart surgery.

18 Jun 2010

University of Utah makes progress against SMA with support of Families of Spinal Muscular Atrophy

18 Jun 2010

Researchers make significant headway in fight against SMA

Researchers at the University of Utah are making strides in understanding and combating a motor neuron disease known as Spinal Muscular Atrophy. The spinal muscular atrophies are a group of inherited diseases that cause progressive degeneration of motor nerves resulting in muscle weakness. The most common form of the disorder, due to the deletion of a critical gene on chromosome 5, is currently the leading cause of inherited infant and child mortality.

18 Jun 2010

NMT Medical receives preliminary results for CLOSURE I PFO/stroke and transient ischemic attack trial

NMT Medical, Inc., an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures, today announced that it has received preliminary results for CLOSURE I, its patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) trial in the U.S.

18 Jun 2010

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in an investigator sponsored Phase I/IIa clinical study of AR-42 (formerly OSU-HDAC42) at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) in adult patients with relapsed or refractory multiple myeloma (MM), chronic lymphocytic leukemia (CLL) or lymphoma.

18 Jun 2010

FDA approves new indication for Tasigna in treatment of rare blood cancer

The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

18 Jun 2010

Phylogeny, Neoprobe announce collaboration to develop head and neck cancer detection technology

Phylogeny, the in situ company, and Neoprobe, a diversified developer of innovative biomedical surgical oncology products, announce their collaboration to develop head and neck cancer detection technology.

18 Jun 2010

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

17 Jun 2010

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.

17 Jun 2010

ACT awarded patent for production processes of RPE cells from hESCs

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued U.S. Patent Number 7736896, which is broadly directed to processes developed by ACT scientists for the production of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs).

17 Jun 2010

Clinical Trial News and Research

NewYork-Presbyterian/Columbia announces recruitment for clinical trial of robotic devices for stroke survivors

Boehringer Ingelheim disappointed with FDA Advisory Committee recommendations on flibanserin NDA for HSDD

Artificial pancreas system reduces risk of nocturnal hypoglycemia

Conscious sedation for glioma resection shortens hospital stay

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Childrens Hospital Los Angeles awarded $2.5M NIH grant to study risk of osteoporosis in spina bifida children

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Curis reports net income of $4.8M for first-quarter 2010: MicroStockProfit.com

Adult stem cell infusion during bypass surgery improves heart function: Study

University of Utah makes progress against SMA with support of Families of Spinal Muscular Atrophy

Researchers make significant headway in fight against SMA

NMT Medical receives preliminary results for CLOSURE I PFO/stroke and transient ischemic attack trial

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

FDA approves new indication for Tasigna in treatment of rare blood cancer

Phylogeny, Neoprobe announce collaboration to develop head and neck cancer detection technology

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

ACT awarded patent for production processes of RPE cells from hESCs

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer